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Abstract 
The present paper eports on the influence of the route of administration and liposome stability on the protective ffect of 
liposome encapsulation of two model antitumor agents, mitoxantrone and doxorubicin. The results demonstrate that 
liposome encapsulation can protect surrounding tissue from the cytotoxic effects of the drugs after subcutaneous ( c) and 
intramuscular (im) administration. The route of administration is an important factor influencing tissue damage. Liposomal 
mitoxantrone caused much less tissue irritation after im injection than after sc injection. Liposome stability is also an 
important factor. Liposomes composed of 'fluid-state' phospholipids only delayed the damaging effects of doxorubicin 
when injected sc. Liposomes with a more rigid nature were much more effective in preventing local tissue damage over a 
longer period of time when administered sc. Results suggest that slow release of liposome-associated drugs may eventually 
cause severe local tissue damage. The incorporation of the hydrophilic lipid derivative distearoylphosphatidylethanolamine- 
poly(ethyleneglycol) (PEG-PE) had no apparent effect on the protective ffect of liposomes after sc administration. © 1998 
Elsevier Science B.V. 
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I. Introduction 
Abbreviations: Chol, cholesterol; DPPC, dipalmitoylphospha- 
tidylcholine; DPPG, dipalmitoylphosphatidylglycerol; EPC, egg- 
phosphatidylcholine; EPG, egg-phosphatidylglycerol; id, intrader- 
real; im, intramuscular; ip, intraperitoneal; PEG-PE, poly(ethyl- 
eneglycol)-distearoylphosphatidylethanolamine; sc, subcutaneous; 
TL, total lipid 
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Peripheral tumors often form metastases in re- 
gional lymph nodes [1]. To achieve ffective therapy, 
it is important to deliver antineoplastic agents selec- 
tively to these lymphatic metastases. After intra- 
venous administration, drug delivery to lymph nodes 
is generally low, because of insufficient ransfer of 
the drug from the blood circulation into the lymphatic 
system. Local injection (e.g., subcutaneous ( c), in- 
tradermal (id), intraperitoneal (ip) and intramuscular 
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(im)) of high concentrations of antineoplastic agents 
may be considered as a relatively effective therapeu- 
tic method since part of the injected drug can be 
taken up by the lymphatic capillaries and subse- 
quently transported to regional ymph nodes. How- 
ever, many antineoplastic agents have vesicant prop- 
erties, i.e. they cause severe tissue damage upon local 
injection. Therefore, local administration of the free 
drug is often not feasible. 
Liposomes have received considerable attention as 
drug carriers to target drugs to regional lymph nodes, 
after local injection [2-4]. Local injection of lipo- 
some-encapsulated drugs has important advantages 
over the use of free drug. Relatively high drug con- 
centrations in regional lymph nodes may be achieved 
as compared to administration f the free drug [5-8]. 
Another important advantage relates to the observa- 
tion that the entrapment of highly irritating drugs in 
liposomes protects urrounding tissue from the direct 
cytotoxic effect of the drug after sc, id, ip, and im 
injection [9-16]. Exposure of tissue to the free drug 
is potentially affected by the rate of clearance of the 
drug from the injection site and release rate of the 
drug from the liposomes. The route of administration 
is an important factor determining disappearance of 
liposomal drug from the injection site [17]. In addi- 
tion, as drug release strongly depends on liposome 
stability, the liposome lipid composition may also 
influence the protective ffect of liposomes. Steric 
stabilization of the liposome surface by incorporation 
of a lipid derivative of poly(ethyleneglycol) (PEG), 
distearoylphosphatidylethanolamine (PEG-PE), stabi- 
lizes liposomes in vivo by reducing interactions with 
components of the biological environment [18]. 
Therefore, the protective ffect of sterically stabilized 
liposomes on the local toxicity of the encapsulated 
drug is of interest as well. 
In the present report, the influence of the route of 
administration a d liposome lipid composition on the 
protective ffect of liposomes against local toxicity of 
two model antitumor drugs, mitoxantrone and doxo- 
rubicin, is described. To study the influence of the 
route of administration, mice were either sc or im 
injected with liposome-encapsulated mitoxantrone. To
study the effect of liposome stability, mice were sc 
injected with doxorubicin encapsulated in 'fluid-state' 
liposomes composed of unsaturated phospholipids or
with doxorubicin encapsulated in 'gel-state' lipo- 
somes composed of saturated lipids. The influence of 
steric stabilization of the liposome surface was stud- 
ied by incorporation of PEG-PE into the liposome 
bilayer, in both fluid-state and gel-state liposomes. 
2. Materials and methods 
2.1. Chemicals 
Egg-phosphatidylcholine (EPC), egg-phosphati- 
dylglycerol (EPG), dipalmitoylphosphatidylcholine 
(DPPC) and dipalmitoylphosphatidylglycerol (DPPG) 
were donated by Lipoid GmbH (Ludwigshafen, FRG). 
Distearoylphosphatidylethanolamine-poly(ethylene- 
glycol)2000 (PEG-PE) was purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). Doxorubicin was 
donated by Pharmachemie BV (Haarlem, The Nether- 
lands). Mitoxantrone was obtained from Lederle 
GmbH (Wolfratshausen, FRG). Cholesterol (Chol) 
and 4-(2-hydroxyethyl) - l -p iperazine-ethane-  
sulphonic acid (Hepes) were obtained from Sigma 
(St. Louis, MO, USA). All other reagents were of 
analytical grade. 
2.2. Preparation of liposomes 
Small mitoxantrone-liposomes (mean size about 
l l0nm, pd< 0.4) composed of EPC:EPG:Chol 
(molar ratio 10:4:4) were prepared by the 'thin-film' 
method. Briefly, a mixture of the appropriate amounts 
of lipids was dissolved in an mixture of 
chloroform/methanol (4:1v/v) and evaporated to 
dryness by rotation under reduced pressure at 40°C. 
After flushing the lipid film with nitrogen for at least 
20 min, the film was hydrated in a sterile solution of 
mitoxantrone (2mg/ml)  dissolved in an isotonic ac- 
etate buffer (pH 5). Liposomes (145 mM total lipid 
(TL)) were sized by sonication until a mean size of 
about 0.1 ~xm was obtained. To obtain a more homo- 
geneous dispersion, liposomes were extruded through 
a 0.2 p~m polycarbonate membrane filter (Nuclepore; 
Costar, Cambridge, MA, USA). The amount of non- 
encapsulated, free mitoxantrone was found to be 
negligible when separated from the liposome formu- 
lation by centrifugation i  a Centrisart I concentration 
tube (Sartorius AG, G6ttingen, FRG). 
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Small doxorubicin-liposomes (mean size varying 
between 85 and 110 nm, pd < 0.2) of several compo- 
sitions were prepared by the 'ammonium sulfate gra- 
dient' method as described by Haran et al. [19]. 
Briefly, a thin film of the appropriate lipids, prepared 
as described above, was hydrated in an ammonium 
sulfate solution (240 mM). Liposomes (120 mM TL) 
were sized by extruding the liposome dispersion se- 
quentially through two 0.1 and 0.05 ~m polycarbon- 
ate membrane filters under nitrogen pressure. The 
external medium of the liposomes was replaced by 
applying the liposomes onto a Sephadex G-25M col- 
umn (PD-10; Pharmacia, Woerden, The Netherlands) 
and subsequent elution with Hepes/glucose buffer 
(10raM Hepes, 1 mM EDTA, 270mM glucose, pH 
7.4). Then liposomes were incubated with doxoru- 
bicin (about 15 Ixmol TL /mg doxorubicin) for 30 rain 
at 60°C. Non-encapsulated doxorubicin was removed 
using the cation exchange resin Dowex 50WX-4 
(Serva, Heidelberg, FRG) [20]. Empty liposomes (i.e. 
devoid of doxorubicin) were prepared in a similar 
way, except hat liposomes were now incubated with 
Hepes/glucose buffer without doxorubicin. 
2.3. Liposome characterization 
Lipid phosphate was determined by the colorimet- 
ric method of Rouser [21]. Mitoxantrone was deter- 
mined spectrometrically in 1% Triton-Xl00 in an 
isotonic acetate buffer (pH 5) at 608 nm. The amount 
of doxorubicin was determined fluorimetrically after 
destruction of the liposomes with acidified ethanol 
(94%, 0.3M HCI; excitation wavelength 490nm, 
emission wavelength 591 nm). Mean particle size was 
determined by dynamic light scattering at 25°C with 
a Malvern 4700 system using a 25 mW He-Ne laser 
(NEC, Tokyo, Japan) and the automeasure version 
3.2 software (Malvern, Malvern, UK). As a measure 
of particle size distribution of the dispersion, the 
system reports a polydispersity index (pd). This index 
ranges from 0.0 for an entirely monodisperse up to 
1.0 for a polydisperse dispersion. 
proximate body weight of 25 g were used. Animals 
received standard laboratory chow and water ad libi- 
tum. The animal experiments adhered to the "Princi- 
ples of Laboratory Animal Health Care". 
To study the influence of the route of administra- 
tion on the protective ffect of liposomes, mice (3 
animals per group) were injected sc into the neck 
region or im into the gastrocnemius muscle with a 
single injection (0.1 ml) of either non-encapsulated, 
free mitoxantrone (0.2 or 0.02 mg) dissolved in an 
isotonic acetate buffer (pH 5) or liposome-encapsu- 
lated mitoxantrone (0.2mg mitoxantrone, 14~mol 
TL). As a control mice were injected sc or im with an 
isotonic acetate buffer (pH 5). To study the influence 
of liposome lipid composition, mice were injected sc 
into the neck region with a single injection (0.1 ml) of 
doxorubicin (0.1 or 0.01 mg) dissolved in Hepes/glu- 
cose buffer or a single dose of doxorubicin (0.1 mg) 
encapsulated in liposomes (about 1 ~mol TL) consist- 
ing of several ipid compositions. As a control mice 
were injected sc with a single dose of empty lipo- 
somes composed of EPC:EPG:Chol (10:1:4). A con- 
trol experiment on tissue reaction after im injection 
of empty liposomes was not performed since local 
tissue damage was not observed in a similar experi- 
ment as reported by Kadir et al. [16]. Mice were 
killed by cervical dislocation 1 or 7 days after injec- 
tion. The site of injection was exposed and examined 
for macroscopic evaluation. Then, in case of sc injec- 
tion, skin at the sc injection site and, in case of im 
injection, the gastrocnemius muscle were collected. 
Tissue samples were left in a 4% formol solution 
prior to dehydration i alcohol and subsequent paraf- 
fin embedding. Tissue blocks were cut into 3 series 
of serial 5~m sections of 20 sections each and 
501xm between the subsequent series and deparaf- 
finized prior to staining with the Goldner (Masson- 
Trichrome) stain. The sections were evaluated by 
light microscopy. The lightmicrographs shown should 
be considered as typical examples of the evaluated 
sectioned material. 
2.4. Animal experiments 
Six weeks old female Swiss mice (mitoxantrone) 
or C57 Black mice (doxorubicin) from the animal 
facility of the University of Nijmegen with an ap- 
3. Results 
3.1. Influence of the route of administration 
The influence of the route of administration  the 
protective ffect of liposomes against the vesicant 
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properties of an encapsulated model antitumor drug 
was studied 1 and 7 days after sc and im administra- 
tion of free and liposome-encapsulated mitoxantrone. 
Results are presented in Table 1. 
Sc administration of 0.2 mg free mitoxantrone r - 
sulted in an inflammatory esponse developing rapidly 
at the injection site. One day post-injection, edema, 
extensive infiltration by inflammatory cells and 
necrosis were observed (Fig. I(A)). Seven days post- 
injection, inflammatory cells and skin damage were 
still present, but repair by formation of connective 
tissue was also observed (Fig. I(B)). A 10-fold lower 
dose of mitoxantrone caused a much less severe 
tissue response; seven days after sc administration of
0.02 mg mitoxantrone a slight inflammatory response 
and repair were observed (Table 1). A single sc 
injection of 0.2 mg liposomal mitoxantrone caused a 
much less intense inflammatory response as com- 
pared to 0.2 mg free mitoxantrone 1 day after injec- 
tion (Fig. 2(A)). However, severity of the tissue 
reaction increased and 7 days after administration of
0.2 mg liposomal mitoxantrone, dema and an exten- 
sive inflammatory response were observed (Fig. 
2(B)). At this time-point, tissue damage was as se- 
vere as tissue damage 7 days after injection of 2.0 mg 
free mitoxantrone. 
Im injection of 0.2 mg free mitoxantrone caused a 
severe inflammatory esponse and necrosis of muscle 
cells one day post-injection (Fig. 3(A)). Seven days 
post-injection the inflammatory response had pro- 
gressed and muscle cell damage was more extensive 
than 1 day post-injection (Fig. 3(B)). A 10-fold lower 
dose (0.02 mg) of free mitoxantrone resulted in a 
much less intense inflammatory esponse 7 days after 
im administration (Table 1). In contrast to 0.2 mg free 
mitoxantrone, an equal dose of liposomal mitox- 
antrone induced virtually no inflammatory esponse 1
and 7 days after im injection (Fig. 4). Seven days 
! 
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Fig. 1. Lightmicrograph of a skin section from a mouse given a single sc injection of 0.2mg free mitoxantrone. (A) One day 
post-injection; extensive infiltration (arrows) and necrosis of muscle cells (Nm) (bar = 100 ixm). (B) Seven days post-injection; ecrotic 
skin (Ns), necrotic muscle cells (Nm), renewed epithelium (R) and slight inflammation (arrows) (bar = 100 ixm). 
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Fig. 2. Lightmicrograph of a skin section from a mouse given a single sc injection of 0.2 mg mitoxantrone encapsulated in small (0.1 Ixm) 
liposomes. (A) One day post-injection; slight inflammatory esponse (arrows) and no muscle cell (M) damage (bar = 100 Ixm). (B) Seven 
days post-injection; extensive inflammatory esponse (arrows) and necrosis of skin tissue (Ns) (bar = 100 Ixm). 
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Table 2 
Tissue reaction after sc administration f free and liposomal doxorubicin 
165 
Formulation/lipid composition Drug dose Tissue reaction Tissue reaction 
(molar atio) (mg) 1 day post-injection 7 days post-injection 
EPC:EPG:Chol (10:1:4) 
Free doxorubicin 0.01 
Free doxorubicin 0.10 
EPC:Chol (2:1) 0.10 
EPC:ChoI:PEG-PE 0.10 
(I.85:1:0.15) 
DPPC:Chol (2:1 ) 0.10 
DPPC:ChoI:PEG-PE 0.10 
(1.85:1:0.15) 
No tissue reaction 
Modest inflammation 
Severe inflammation a d 
necrosis of muscle cells 
Slight inflammation, 
minimal tissue damage 
Slight inflammation, 
no tissue damage 
Slight inflammation, 
no tissue damage 
Slight inflammation, 
no tissue damage 
ND" 
Modest inflammation 
Severe tissue damage and 
necrosis of muscle cells 
Necrosis of dermis and muscle cells 
Necrosis of dermis and 
muscle cells 
Modest inflammation, 
no tissue damage 
Modest inflammation, 
minimal tissue damage 
Small (0.1 Ixm, pd < 0.2) liposomes of several compositions were injected at a dose of about 1 Ixmol TL. 
Not determined. 
after administration of liposomal mitoxantrone, loose 
connective tissue was observed at the site of injection 
and in all animals tissue reaction was even less than 
after administration of a 10-fold lower dose of free 
mitoxantrone. 
3.2. Influence of liposome stabili~ 
The influence of liposome stability on the protec- 
tive effect of liposomes against dermal toxicity was 
studied 1 and 7 days after sc administration of free 
doxorubicin and doxorubicin encapsulated in lipo- 
somes with relatively 'fluid' bilayers and liposomes 
with more 'rigid' bilayers. Liposomes with the more 
fluid bilayers were composed of EPC:Chol (2:1, mo- 
lar ratio) with or without PEG-PE (5 mol%). Lipo- 
somes which are expected to be more stable against 
release of the entrapped rug, rigid liposomes, were 
composed of DPPC:Chol (2:1, molar) with or without 
PEG-PE (5 mol%). Results of histological examina- 
tions of surrounding tissue are given in Table 2. 
Free doxorubicin at a dose of 0.1 mg, caused se- 
vere and rapid damage to surrounding tissue. One day 
post-injection, extensive infiltration by inflammatory 
cells was observed in the epithelial and adipose lay- 
ers (Fig. 5(A)). Cells were severely damaged and 
necrotic areas were observed. Seven days post-injec- 
tion tissue damage was still severe. Moreover, the 
area of inflammation was slightly increased (Fig. 
5(B)). A 10-fold lower dose of doxorubicin caused 
much less tissue response as only few inflammatory 
cells were observed 1 and 7 days after injection 
(Table 2). In control animals receiving empty lipo- 
somes, no adverse tissue reaction was observed 1day 
post-injection. 
Tissue response was much milder 1 day after sc 
administration of 0.1 mg liposome-encapsulated dox- 
orubicin as compared to the free drug. A modest 
infiltration of inflammatory cells was observed when 
0.1 mg doxorubicin was encapsulated in EPC:Chol 
and EPC:Chol:PEG-PE liposomes 1 day post-injec- 
tion (Table 2, Fig. 6). Tissue damage was less than 
seen after administration of 0.1 mg free doxorubicin 
as no gross lesions were observed. Inflammation was 
restricted to the dermis and was not observed in the 
underlying muscle layer. Surprisingly, 7 days post-in- 
jection, the inflammatory responses had progressed 
and necrotic areas were observed in the dermis and 
underlying muscle layer in all animals (Fig. 6(B)). 
Skin toxicity appeared to be even more severe when 
compared to skin lesions 7 days after administration 
of 0. l mg free doxorubicin. Administration of dox- 
orubicin encapsulated in the more rigid DPPC:Chol 
and DPPC:ChoI:PEG-PE liposomes induced a mild, 
but prolonged inflammatory response. Although nu- 
merous inflammatory cells were observed at both 
observation time-points, tissue damage was minimal 
(Table 2, Fig. 7). Compared to day 1, the inflamma- 
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B. 
Fig. 4. Lightmicrograph of a skin section from a mouse given a single im injection of 0.2 mg mitoxantrone encapsulated in small (0. l Ixm) 
liposomes. (A) One day post-injection; virtually no inflammation or muscle cell (M) damage (bar= 40lxm). (B) Seven days 
post-injection; o muscle cell damage (M), loose connective tissue (C) with little inflammatory esponse (bar = 400 p~m). 
tory response was only slightly increased at 7 days 
post-injection. 
4. Discussion 
Several papers have appeared that demonstrate the 
potential of liposomes to protect surrounding tissue 
against the local toxic effects of highly irritating 
agents after sc and im administration. [9,11-13,16]. 
The influence of the route of administration and the 
liposome lipid composition on the protective ffect of 
liposomes have received minimal attention until now. 
This paper reports on the influence of these two 
factors potentially affecting the protective ffect of 
liposome encapsulation against the vesicant proper- 
ties of two model anti-tumor drugs. The effect of the 
route of administration was studied after sc and im 
administration of mitoxantrone-containing liposomes, 
Fig. 3. Lightmicrograph of a skin section from a mouse given a single im injection of 0.2 mg free mitoxantrone. (A) One day 
post-injection; inflammation (arrows) and necrosis of muscle cells (Nm) (bar=401xm). (B) Seven days post-injection; severe 
inflammatory esponse (arrows) and extensive muscle cell damage (Nm) (bar = 40 fxm). 
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Fig. 5. Lightmicrograph of a skin section from a mouse given a single sc injection of 0.1 mg free doxorubicin. (A) One day post-injection; 
extensive inflammation (arrows) in both skin epithelium and muscle layer, and necrotic muscle cells (Nm) (bar = 100 p~m). (B) Seven 
days post-injection; inflammatory cells (arrows) and necrosis of muscle cells (Nm), almost complete disappearance of muscle layer 
(bar = 100 p,m). 
the effect of liposome lipid composition was studied 
after sc administration of doxorubicin-containing li- 
posomes of several lipid compositions. 
Mitoxantrone is an anthracenedione derivative with 
a spectrum of clinical activity similar to the anthra- 
cycline doxorubicin [22]. Local tissue damage of 
mitoxantrone has been reported only occasionally and 
is usually less severe than tissue damage caused by 
local administration of doxorubicin [10]. However, 
under the chosen conditions, we observed severe 
tissue damage after sc administration of 0.2 mg free 
mitoxantrone. Doxorubicin has proven to be highly 
toxic to surrounding tissue when administered locally 
[9-12]. Presumably, local tissue damage is caused by 
a direct cytotoxic effect of the drug. Both drugs have 
a high affinity for cellular DNA resulting in inhibi- 
tion of DNA synthesis and cell death [23,24]. With 
respect o skin injury, there have been speculations 
that doxorubicin released from dying cells in the 
dermis induces damage and death in neighbouring 
cells, only to be released again, thus forming a 
repetitive cycle. This would account for the progres- 
sive nature of the tissue damage [9,25]. The results 
presented here indicate that mitoxantrone and doxo- 
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Fig. 6. Lightmicrograph of a skin section from a mouse given a single sc injection of 0.1 mg doxorubicin encapsulated in fluid-state 
liposomes composed of EPC:Chol. (A) One day post-injection; modest infiltration of inflammatory cells (arrows) no muscle cell damage 
(M) (bar = 100 Ixm). (B) Seven days post-injection; inflammatory esponse (arrows) and necrotic areas in skin (Ns) and necrosis of 
muscle cells (Nm), almost complete disappearance of muscle layer (bar = 100 Ixm). 
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rubicin at the doses tested, are both progressively 
vesicant and cause similar patterns of tissue damage 
when injected sc. 
L iposome encapsulation of mitoxantrone reduced 
local toxicity after sc and im administration. Local 
tissue damage was strongly dependent on the route of 
Fig. 7. Lightmicrograph of a skin section from a mouse given a single sc injection of 0.1 mg doxorubicin encapsulated in rigid liposomes 
composed of DPPC:Chol. (A) One day post-injection; mild infiltration of inflammatory cells (arrows), no muscle cell damage (M) 
(bar= 100p~m). (B) Seven days post-injection, inflammation (arrows), but no damage in epithelium (E) or muscle layer (M) 
(bar = 100 i~m). 
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administration. Initially, surrounding tissue was pro- 
tected efficiently against the toxic effects of the 
encapsulated mitoxantrone after injection via both 
routes of administration. However, seven days post- 
injection remarkable differences were observed in the 
protective ffect of liposomes following sc and im 
injection. At this time-point, encapsulation of lipo- 
somes dramatically reduced toxic effects after im 
administration but not after sc administration. The 
observed differences between the protective ffect 
after sc and im administration may be ascribed to the 
more complete and faster clearance of injected mate- 
rial after im injection than after sc administration 
[17]. Differences in the rate of clearance from the im 
and sc injection site are attributed to a richer supply 
of blood in muscle tissue and increased blood flow 
through muscles during body movement of the ani- 
mal [17,27]. Released rugs may be cleared rapidly 
from the im injection site. As surrounding tissue will 
only be exposed to very low concentrations of the 
free drug, tissue damage will be negligible. In con- 
trast, the prolonged inflammatory response observed 
following sc administration of mitoxantrone- and 
doxorubicin-containing liposomes may be the result 
of a large proportion of the injected liposome dose 
remaining at the injection site for a long period of 
time [3]. Lack of clearance from the injection site 
may result in accumulation of the released rug and 
thus in prolonged exposure of surrounding tissue to 
high concentrations of the cytotoxic drug. 
It is of interest o study the ability of liposomes to 
reduce vesicant properties of encapsulated antitumor 
drugs in relation to the liposome lipid composition 
after sc administration. The protective ffect of lipo- 
somes on the vesicant properties of doxorubicin has 
been reported previously [9-12]. However, little at- 
tention has been paid to liposome stability. The pre- 
sent results demonstrate hat liposome stability is an 
important factor determining the protective ffect of 
liposomes. Initially, 1 day after sc injection, all lipo- 
some compositions protected surrounding tissue 
against the damaging effects of mitoxantrone and 
doxorubicin. However, seven days after administra- 
tion, marked differences were observed. At this 
time-point, doxorubicin encapsulated in EPC:Chol 
liposomes was at least as toxic as an equal dose of 
the free drug, whereas doxorubicin encapsulated in
DPPC:Chol liposomes induced only mild inflamma- 
tory response. As the more rigid membranes of 
DPPC:Chol liposomes generate more stable lipo- 
somes with regard to leakage of the liposome content 
as compared to liposomes composed of EPC:Chol 
[26], the stronger protective ffect of DPPC:Chol may 
be attributed to slower release of the encapsulated 
drug as compared to the 'fluid' EPC:Chol liposomes. 
These results are in agreement with the observation 
on tissue damage caused 7 days after sc injection of 
mitoxantrone encapsulated in liposomes which were 
also composed of 'fluid-state' lipids. 
The effect of inclusion of PEG-PE into the lipo- 
somes was negligible. Apparently, exposure of sur- 
rounding tissue to drug is not significantly influenced 
by steric stabilization of the liposome surface. 
It is tempting to speculate on the basis of the 
results presented here that encapsulation of doxoru- 
bicin in liposomes with more rigid bilayers could be 
used safely when treatment consists of local adminis- 
tration. However, it should be realized that even in 
the case of rigid liposomes damage to local tissue 
may be severe after prolonged exposure to a low, but 
persistent dose of vesicant antineoplastic agents, such 
as mitoxantrone or doxorubicin, slowly released from 
liposomes. Therefore, it is of critical importance to 
assess long-term local toxicity of liposome-encapsu- 
lated mitoxantrone or doxorubicin before designing 
treatment protocols on the basis of local administra- 
tion of these drugs. 
In conclusion, liposomes can protect surrounding 
tissue from the toxic effects of the encapsulated 
antineoplastic agents mitoxantrone and doxorubicin. 
The route of administration is an important factor 
influencing tissue damage. The protective ffect of 
liposomes on local toxicity of mitoxantrone is much 
stronger after im than after sc administration. This 
observation is attributed to the faster and more com- 
plete clearance of the vesicant drug after im injection 
as compared to sc injection. Furthermore, it was 
demonstrated that the protective ffect of liposomes 
on the vesicant properties of doxorubicin is stronger 
for liposomes with a more rigid nature. Although 
liposomes with more fluid bilayers initially protect 
surrounding tissue from direct dermal toxicity of the 
encapsulated drug, slow release may result in pro- 
longed and persistent exposure to low doses of the 
toxic drug and may be a serious cause of local tissue 
damage. The incorporation of PEG-PE had no appar- 
172 C. Oussoren et al. / Biochimica et Biophysica Acta 1369 (1998) 159-172 
ent effect on the protective ffect of liposomes after 
sc administration. 
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